CD4-specific Telomerase Peptide Vaccine UCPVax clinical trials
How each study uses CD4-specific Telomerase Peptide Vaccine UCPVax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CD4-specific Telomerase Peptide Vaccine UCPVax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- UCPVax
- 3
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Studies
Open first, then newest update. How each study uses CD4-specific Telomerase Peptide Vaccine UCPVax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT GlioblastomaNot yet recruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT07347210Written as UCPVaxHow we know
- Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerCompletedPhase 2Centre Hospitalier Universitaire de BesanconNCT04263051Written as UCPVax + NivolumabHow we know
- Universal Cancer Peptide-based Vaccination in Metastatic NSCLCCompletedPhase 1/2Centre Hospitalier Universitaire de BesanconNCT02818426Written as UCPVaxHow we know
- Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)CompletedPhase 2Centre Hospitalier Universitaire de BesanconNCT03946358Written as UCPVaxHow we know
Given beside what is tested · 2 — CD4-specific Telomerase Peptide Vaccine UCPVax is usual care or a partner of the new treatment
- Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaRecruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT05528952Written as UCPVaxHow we know
- Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in GlioblastomaCompletedPhase 2Centre Hospitalier Universitaire de BesanconNCT04280848Written as UCPVaxHow we know